- Stocks
- Pharma & Healthcare
- Akums Drugs and Pharmaceuticals
Akums Drugs and Pharmaceuticals share price
NSE: AKUMSPharma & HealthcareDrug Manufacturers - Specialty & Generic
Akums Drugs and Pharmaceuticals at a glance
Akums Drugs and Pharmaceuticals (NSE: AKUMS) closed at ₹690.85 on 22 Oct 2026, down 0.17% on the day. With a market capitalisation of ₹10,874 Cr, it ranks 533rd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 41.5× trailing earnings, against a return on equity of 7.7% in FY26. Over the past year the share price has risen 50.2%. Its 52-week range is ₹409.30 (21 Jan 2026) to ₹838.80 (23 Sep 2026); the last close is 17.6% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹338 Cr (+2.9% year on year) and net profit ₹15 Cr (−44.9%), on a standalone basis. Promoters held 75.26% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹10,874 CrRank 533 on NSE
- P/E (trailing)
- 41.5×
- Price to book
- 2.15×FY26
- EPS (TTM)
- ₹7.29to Q4 FY26
- ROE
- 7.7%FY26
- ROCE
- 11.4%FY26
- Debt to equity
- 0.02FY26
- Net profit margin
- 5.9%FY26
- Book value / share
- ₹216.41FY26
- 52-week high
- ₹838.8023 Sep 2026
- 52-week low
- ₹409.3021 Jan 2026
- 1-year return
- +50.2%
- RSI (14-day)
- 31.9
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −0.17% | −11.0% | −15.9% | −0.7% | +50.2% |
Akums Drugs and Pharmaceuticals quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹317 Cr | ₹328 Cr | ₹337 Cr | ₹329 Cr | ₹332 Cr | ₹309 Cr | ₹369 Cr | ₹338 Cr |
| Revenue YoY | +0.5% | −26.5% | −11.9% | +10.2% | +4.8% | −5.8% | +9.2% | +2.9% |
| Net profit | ₹42 Cr | ₹50 Cr | ₹41 Cr | ₹28 Cr | ₹45 Cr | ₹23 Cr | ₹28 Cr | ₹15 Cr |
| Net profit YoY | — | −4.5% | +40.3% | — | +7.1% | −53.4% | −31.7% | −44.9% |
| Net margin | 13.2% | 15.3% | 12.2% | 8.4% | 13.5% | 7.6% | 7.6% | 4.5% |
| EPS | ₹2.93 | ₹3.38 | ₹2.69 | ₹1.80 | ₹2.93 | ₹1.53 | ₹1.84 | ₹0.99 |
Akums Drugs and Pharmaceuticals financials
| Item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | ₹3,672 Cr | ₹3,655 Cr | ₹4,178 Cr | ₹4,118 Cr | — |
| Operating profit | −₹180 Cr | ₹225 Cr | −₹19 Cr | ₹329 Cr | — |
| Net profit | −₹251 Cr | ₹98 Cr | ₹1 Cr | ₹344 Cr | — |
| EPS (₹) | −₹18.00 | ₹7.00 | ₹0.00 | ₹23.00 | — |
| Cash from operations | ₹32 Cr | ₹177 Cr | ₹498 Cr | ₹465 Cr | — |
| Total debt | ₹13 Cr | ₹116 Cr | ₹78 Cr | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹622 Cr | ₹717 Cr | ₹710 Cr | ₹3,047 Cr | ₹3,313 Cr |
Akums Drugs and Pharmaceuticals shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 75.26% | 75.26% | 75.26% | 75.26% | 75.26% | 75.26% |
| Foreign institutions | 5.77% | 4.24% | 2.28% | 1.15% | 1.37% | 1.91% |
| Domestic institutions | 7.40% | 8.85% | 9.28% | 14.40% | 14.35% | 13.44% |
| Non-institutions | 8.85% | 8.93% | 10.46% | 6.46% | 6.29% | 6.66% |
Akums Drugs and Pharmaceuticals vs peers
The listed Pharma & Healthcare companies nearest to Akums Drugs and Pharmaceuticals by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| CORONACORONA Remedies | ₹2,024.70 | −0.26% | — | ₹12,360 Cr | 66.8 | 24.8% |
| RAINBOWRainbow Childrens Medicare | ₹1,205.70 | −0.27% | −9.4% | ₹12,245 Cr | 43.9 | — |
| SUDEEPPHRMSudeep Pharma | ₹984.90 | +1.02% | — | ₹11,124 Cr | 66.2 | — |
| METROPOLISMetropolis Healthcare | ₹532.25 | −0.03% | +9.2% | ₹11,035 Cr | 57.9 | — |
| AKUMSAkums Drugs and Pharmaceuticals | ₹690.85 | −0.17% | +50.2% | ₹10,874 Cr | 41.5 | — |
| PARKHOSPSPark Medi World | ₹220.45 | −0.74% | — | ₹9,522 Cr | 32.1 | — |
| BLUEJETBlue Jet Healthcare | ₹499.60 | +1.50% | −23.8% | ₹9,456 Cr | 35 | — |
Ask anything about Akums Drugs and Pharmaceuticals
Pivot answers on the live chart with evidence you can check, and tests strategies against AKUMS's own history. Try: “Why has AKUMS moved over the last three months?” · “Backtest a 50-day moving-average crossover on AKUMS over five years” · “Compare AKUMS with CORONA on margins and valuation”
Frequently asked questions about Akums Drugs and Pharmaceuticals
What is the share price of Akums Drugs and Pharmaceuticals today?
Akums Drugs and Pharmaceuticals (NSE: AKUMS) last closed at ₹690.85 on 22 Oct 2026. Its 52-week high is ₹838.80 and its 52-week low is ₹409.30.
What is the market cap of Akums Drugs and Pharmaceuticals?
Akums Drugs and Pharmaceuticals' market capitalisation is ₹10,874 Cr (₹10,874 Cr) at the 22 Oct 2026 close, ranking 533rd among the NSE companies Pivot tracks.
What is the P/E ratio of Akums Drugs and Pharmaceuticals?
Akums Drugs and Pharmaceuticals trades at a trailing P/E of 41.5. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 57.9.
What is the ROE and ROCE of Akums Drugs and Pharmaceuticals?
Return on equity was 7.7% in FY26 and return on capital employed was 11.4% in FY26 (consolidated figures).
Is Akums Drugs and Pharmaceuticals a debt-free company?
Akums Drugs and Pharmaceuticals is close to debt-free: its debt-to-equity ratio was 0.02 in FY26.
What were Akums Drugs and Pharmaceuticals' latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Akums Drugs and Pharmaceuticals reported revenue of ₹338 Cr, +2.9% year on year, and net profit of ₹15 Cr, −44.9% year on year.
How has Akums Drugs and Pharmaceuticals stock performed over the last year?
Akums Drugs and Pharmaceuticals' share price has risen 50.2% over the past year, −0.7% over three months and −15.9% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Akums Drugs and Pharmaceuticals?
As of 30 Jun 2026: promoters 75.26%, foreign institutions 1.91%, domestic institutions 13.44%, non-institutions 6.66%.
Who are Akums Drugs and Pharmaceuticals' competitors?
The listed Pharma & Healthcare companies closest to Akums Drugs and Pharmaceuticals by market cap are CORONA Remedies, Rainbow Childrens Medicare, Sudeep Pharma, Metropolis Healthcare, Park Medi World and Blue Jet Healthcare.
Is Akums Drugs and Pharmaceuticals a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Akums Drugs and Pharmaceuticals' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on AKUMS against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, standalone where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with A · all NSE stocks · this page as text